Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Clinical characteristics and treatment evaluation of T-cell lymphoblastic lymphoma in Chinese children and adolescents：a multicenter clinical study of China-net childhood lymphoma-lbl-2017

Blood (2025) 146 (Supplement 1): 7155.

https://doi.org/10.1182/blood-2025-7155

Published: 2025

Journal Articles

The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma

Caiyan Zhang, Ying Liu, Jing Yang, Yueping Jia, Leping Zhang, Yunpeng Dai, Guotao Guan, Yang Li, Keyan Yang, Qinlong Zheng, Yongh Zhang

Blood (2025) 146 (Supplement 1): 5314.

https://doi.org/10.1182/blood-2025-5314

Published: 2025

Journal Articles

Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study

Blood (2025) 146 (Supplement 1): 797.

https://doi.org/10.1182/blood-2025-797

Published: 2025

Journal Articles

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Alessandra Tucci, Yair Herishanu, Juan Dupont, Sarit Assouline, Lori Leslie, Thor Hoyer, Pier Luigi Zinzani, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 1801.

https://doi.org/10.1182/blood-2025-1801

Published: 2025

Journal Articles

Improve therapeutic response through inhibition of endosome machinery in multiple myeloma

Yutong Wang, Liuting Chen, Yung-hsing Huang, Jin He, Li Bao, Yihui Fan, Pei Lin, Qing Yi, Jing Yang

Blood (2025) 146 (Supplement 1): 3917.

https://doi.org/10.1182/blood-2025-3917

Published: 2025

Journal Articles

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Wojciech Jurczak, Ana Basquiera, Isabelle Fleury, Sujun Gao, Arpad Illes, Andras Masszi, Antonio Pinto, Sanne Lugthart, Omur Sevindik, Iryna Kriachok, Elizabeth Phillips, Fei Li, Chan Cheah, Yan Xu, Mohammed Z.H. Farooqui, Jing Yang, Fangfang Lv

Blood (2025) 146 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2025-3570

Published: 2025

Journal Articles

Impact of ALK fusion variants and genetic profiles on prognosis in Chinese pediatric patients with ALK-positive anaplastic large cell lymphoma

Blood (2025) 146 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2025-3526

Published: 2025

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Lei Yang, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6475.

https://doi.org/10.1182/blood-2024-209754

Published: 2024

Journal Articles

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Xin-di Liu, Jia Cong, Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2024-203066

Published: 2024

Journal Articles

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Na Yao, Xin Li, Jing Yang, Jia Cong, Liang Wang

Blood (2024) 144 (Supplement 1): 6541.

https://doi.org/10.1182/blood-2024-203548

Published: 2024

Journal Articles

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Jing Yang, Liang Wang

Blood (2024) 144 (Supplement 1): 6540.

https://doi.org/10.1182/blood-2024-202904

Published: 2024

Journal Articles

Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 681.

https://doi.org/10.1182/blood-2024-204200

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Wojciech Jurczak, Isabelle Fleury, Antonio Pinto, Sanne Lugthart, Omur Gokmen Sevindik, Iryna Kryachok, Elizabeth Phillips, Fei Li, Chan Y. Cheah, Jing Yang, Yan Xu, Siyang Leng, Fangfang Lv

Blood (2024) 144 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2024-201578

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Pier Luigi Zinzani, Juan Carlos Dupont, Alessandra Tucci, Jing Yang, Yan Xu, Siyang Leng, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 3016.

https://doi.org/10.1182/blood-2024-201646

Published: 2024

Journal Articles

Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma

Liang Wang, Jing Yang, Liqiang Wei

Blood (2023) 142 (Supplement 1): 6210.

https://doi.org/10.1182/blood-2023-182678

Published: 2023

Journal Articles

Efficacy and Safety of Modified BV-AVD-R Regimen in Chinese Children with Previously Untreated Intermediate- and High-Risk Classical Hodgkin's Lymphoma: An Open Label, Non-Randomized, Single-Arm, Phase 2 Study from Single Center

Li Ying, Nan Li, Shuang Huang, Ling Jin, Jing Yang, Chunju Zhou, Xiaoling Wang, Yanlong Duan

Blood (2023) 142 (Supplement 1): 6212.

https://doi.org/10.1182/blood-2023-184375

Published: 2023

Journal Articles

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Blood (2023) 142 (Supplement 1): 6088.

https://doi.org/10.1182/blood-2023-188415

Published: 2023

Journal Articles

Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)

Blood (2023) 142 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2023-188761

Published: 2023

Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in the Treatment of Pediatric Patients with R/R Hodgkin Lymphoma: Results of a Real World Setting Study

Li Ying, Nan Li, Chunju Zhou, Shuang Huang, Ling Jin, Jing Yang, Miaomiao Shao, Hao Sun, Xiaoling Wang, Yanlong Duan

Blood (2023) 142 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2023-182590

Published: 2023

Journal Articles

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2023-188173

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical characteristics and treatment evaluation of T-cell lymphoblastic lymphoma in Chinese children and adolescents：a multicenter clinical study of China-net childhood lymphoma-lbl-2017

The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma

Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study

Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma

Improve therapeutic response through inhibition of endosome machinery in multiple myeloma

Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study

Impact of ALK fusion variants and genetic profiles on prognosis in Chinese pediatric patients with ALK-positive anaplastic large cell lymphoma

Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Polatuzumab Vedotin-Based Regimens As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Orelabrutinib with or without Anti-CD20 Monoclonal Antibodies Is Highly Effective and Well Tolerated As First-Line Therapy for Marginal Zone B Cell Lymphoma

Rapid Step-up Dosing Schedule of Glofitamab Is Feasible for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Efficacy and Safety Analysis of Combination Therapy Based on Liposomal Mitoxantrone (Lipo-MIT) in Relapsed/Refractory NK/T-Cell Lymphoma

Efficacy and Safety of Modified BV-AVD-R Regimen in Chinese Children with Previously Untreated Intermediate- and High-Risk Classical Hodgkin's Lymphoma: An Open Label, Non-Randomized, Single-Arm, Phase 2 Study from Single Center

Prognostic Impact of Minimal Disseminated Disease (MDD) and Minimal Residual Disease (MRD) in Chinese Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

Clinical Pathology Characteristics of 221 Pediatric Anaplastic Large Cell Lymphoma-3 Years Follow up and Experience from China Net Childhood Lymphoma(CNCL)

Brentuximab Vedotin Combined with Chemotherapy in the Treatment of Pediatric Patients with R/R Hodgkin Lymphoma: Results of a Real World Setting Study

Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only